Ceftizoxime  (PDF Version)


Antibiotic Class:

Third-Generation Cephalosporin


Antimicrobial Spectrum:

Staphylococcus aureus (methicillin susceptible), Coagulase negative Staphylococci, Streptococcus pneumoniae (penicillin susceptible), Streptococcus spp., Haemophilus influenzae, Moraxella catarrhalis, Neisseria meningitides, Neisseria gonorrhoeae, Enterobacteriaceae, E. coli


Mechanism of Action:

Cephalosporins exert bactericidal activity by interfering with bacterial cell wall synthesis and inhibiting cross-linking of the peptidoglycan. The cephalosporins are also thought to play a role in the activation of bacterical cell autolysins which may contribute to bacterial cell lysis.



Cephalosporins exhibit time-dependent killing (T > MIC)



Dose of 1g: Cmax: 84 mcg/L; Half-life: 1.8 hours; Volume of distribution: 28L; Table 11


Adverse Effects:

Hypersensitivity: Maculopapular rash, Urticaria, Pruritis, Anaphylaxis/angioedema, eosinophilia

Hematologic: Hypoprothrombinemia, Neutropenia, Leukopenia, Thrombocytopenia

GI: Diarrhea, C. difficile disease

Renal: Interstitial nephritis

Table 14



IV: Powder for reconstitution: 500mg, 1g, 2g, 10g, 20g

      Intravenous Solution: 1g/50mL, 2 g/50mL


Dosing in adults:

Gonorrhea: 1 g IM x 1 dose

Skin and/or subcutaneous tissue infection: 1 g IV/IM q8-12h

Intra-abdominal infection: 1 g IV/IM q8-12h

Meningitis: 1 g IV/IM q8h or 2g IV/IM q8-12h

UTI: 1-2 g IV/IM q8-12h


Dosing in pediatrics:

100-200mg/kg/day divided q6-8h

Table 12


Disease state based dosing:

Renal failure:  CrCl > 80mL/min: standard dosing

                       CrCl 50-80mL/min: 0.75g-1.5g q8h

                       CrCl 5-49mL/min: 0.5g-1g q12h

                       CrCl < 5mL/min: 0.5g q24h OR 1q q48h

Hepatic failure:  No dosing changes recommended at this time.



Precautions: hypersensitivity to penicillins, history of gastrointestinal disease, particularly colitis,

renal impairment


Drug Interactions:

Live Typhoid Vaccine: decreased immunological response to the typhoid vaccine



Category B: No evidence of risk in humans but studies inadequate.


Monitoring Requirements:

Therapeutic:  Culture and sensitivities, serum levels, signs and symptoms of infection, white blood cell count

Toxic:  Urinalysis, BUN, SCr, AST and ALT, skin rash, Neutropenia and leukopenia, Prothrombin time in patients with renal or hepatic impairment or poor nutritional state, as well as patients receiving a protracted course of antimicrobial therapy, and patients previously stabilized on anticoagulant therapy.


Brand names/Manufacturer:  Cefizox/Fujisawa